Tilray’s (TLRY) aggressive expansion into Germany’s medical cannabis scene signals a drive to claim more of the global spotlight. The company posted fiscal 2025 highlights that include $821 million in net revenue, up 4%, and a jump in cannabis segment gross margin from 33% to 40%. This financial delivery comes as Tilray strengthened its balance sheet, cutting debt by nearly $100 million and building a $256 million liquidity buffer.
All this is happening as the cannabis sector is gaining traction, as global market value could approach $444 billion by 2030. The recent surge in optimism, especially after high-profile endorsements and stronger legalization trends, has reignited momentum across medical cannabis players.
